Nicoletta Loggia
Hoofd Techniek/Wetenschap/O&O bij ORCHARD THERAPEUTICS PLC
Profiel
Dr. Nicoletta Loggia is an Independent Director at Candel Therapeutics, Inc. and a Chief Technical Officer at Orchard Therapeutics Plc.
She is on the Board of Directors at Candel Therapeutics, Inc. She received her doctorate degree from the University of Pavia.
Actieve functies van Nicoletta Loggia
| Bedrijven | Functie | Begin |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Hoofd Techniek/Wetenschap/O&O | 09-09-2021 |
| CANDEL THERAPEUTICS, INC. | Directeur/Bestuurslid | 07-06-2023 |
Opleiding van Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
